Bluesky Facebook Reddit Email

Looking ahead to new biomarkers, clinical trials, and potential treatments for Alzheimer's

10.26.20 | NIH/National Institute on Aging

Sony Alpha a7 IV (Body Only)

Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.

WHAT: National Institute on Aging (NIA) experts will be available to further explain and analyze some of the latest research as presented at the 13th Annual International Conference on Clinical Trials for Alzheimer's Disease (CTAD) . This year's digital event will include presentations from NIA researchers and NIA-funded scientists on topics such as anti-amyloid treatments, biomarkers , and new late-stage clinical trials in Alzheimer's disease and related dementias.

"Biomarkers, in particular those using blood or plasma, are seen as a crucial step to help researchers and doctors screen people for early Alzheimer's even before cognitive changes occur," said Eliezer Masliah, M.D., director, NIA Division of Neuroscience. "In addition to featuring biomarker research, CTAD presentations highlight how NIA is funding trials at multiple stages across a diverse range of drug and mechanistic targets, including non-drug trials looking at nutrition, exercise, and combinations."

NIA, part of the U.S. National Institutes of Health, is the single largest public funder of Alzheimer's and related dementias research in the U.S. Through its multi-pronged approach, NIA currently is supporting more than 230 active clinical trials as well as innovative research to prime and redesign drug discovery for these devasting diseases.

WHEN:
NIA experts will be available for embargoed interviews beginning October 26 and during CTAD, November 4-7 .

WHO:

NIA-SUPPORTED PRESENTATION HIGHLIGHTS:
The following are just a few of the CTAD presentations with NIA involvement or support; please note, this research is embargoed until the start of the presentations:

Wednesday, November 4

Thursday, November 5

Friday, November 6

###

About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related cognitive change and neurodegenerative diseases via NIA's Alzheimer's Disease Education and Referral (ADEAR) Center website . For information about a broad range of aging topics, visit the main NIA website and stay connected .

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov .

NIH...Turning Discovery Into Health®

Keywords

Contact Information

Source

How to Cite This Article

APA:
NIH/National Institute on Aging. (2020, October 26). Looking ahead to new biomarkers, clinical trials, and potential treatments for Alzheimer's. Brightsurf News. https://www.brightsurf.com/news/L59EJ538/looking-ahead-to-new-biomarkers-clinical-trials-and-potential-treatments-for-alzheimers.html
MLA:
"Looking ahead to new biomarkers, clinical trials, and potential treatments for Alzheimer's." Brightsurf News, Oct. 26 2020, https://www.brightsurf.com/news/L59EJ538/looking-ahead-to-new-biomarkers-clinical-trials-and-potential-treatments-for-alzheimers.html.